RCT Data Needed on Phosphate-Lowering Agents and NDD-CKD Outcomes
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Hyperphosphatemia
Phosphate Binder Dissatisfaction May Affect Patient Outcomes
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
FDA Wants Another Study Before Deciding on Tenapanor Approval
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Tenapanor May Improve Phosphate Normalization in the Dialysis Population
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Nicotinamide May Improve Phosphate Control in Hemodialysis Patients
Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.
Phosphate Binder Found to Raise Blood Pressure in CKD
Investigators found a clinically significant difference in systolic blood pressure among patients with stage 3b to 4 chronic kidney disease taking and not taking lanthanum carbonate.
Tenapanor Reduces Elevated Serum Phosphate in CKD
Adverse events limited to softened stool, modest increase in bowel movement freqeuncy
First-in-Class Treatment Shows Promise in Hyperphosphatemia Trial
The trial demonstrated a statistically significant difference in serum phosphorus levels for the tenapanor group over the placebo group.
